[Hormonal contraceptives of differentiated composition -- effects on thrombocyte function (author's transl)].
The number, proliferation, and aggregation of thrombocytes, platelet adhesiveness, and thromboblastographic values were investigated in the context of 52 women, who were on a compound hormonal contraceptive with threefold-differentiated gestagen, and of ten women with a compound hormonal contraceptive of two-fold gestagen differentiation. Tests were conducted over six months. Significant deviations from normal values were recordable. No definite conclusions, however, can be drawn from such individual observations. Disorders in thrombocyte function and change in thromboblastographic values, when considered with all their implications, are likely to suggest the presence of effects from hormonal contraceptives. Yet, both type and concentrations of oestrogens and gestagens are of minor importance to such change. Nevertheless, somewhat higher risk of thrombo-embolism should be assumed, if other conductive factors are present, at the same time.
D001792:Blood Platelets / Q000187:drug effects; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D009640:Norethindrone / Q000009:adverse effects / Q000031:analogs & derivatives; D000077563:Norethindrone Acetate; D009644:Norgestrel / Q000009:adverse effects; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D013916:Thrombelastography
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D009644:Norgestrel; D004997:Ethinyl Estradiol; D000077563:Norethindrone Acetate; D009640:Norethindrone
Beeinflussung der Thrombozytenfunktion durch hormonale Kontrazeptiva unterschiedlicher Zusammensetzung.